This Article Full Text (PDF) All Versions of this Article: 0897190008318233v1 21/5/371    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Clayton, J. K. Articles by Starr, J. A. Search for Related Content Social Bookmarking                         What's this?

Novel Approaches to the Treatment of Sepsis Syndrome

Department of Clinical Pharmacy, Princeton Baptist Medical Center, Birmingham, Alabama, jennifer.clayton{at}bhsala.com

Jessica A. Starr, PharmD, BCPS

Auburn University, Harrison School of Pharmacy, Alabama

Sepsis, severe sepsis, and septic shock are common diagnoses in intensive care units worldwide. In the United States, it is estimated that 750 000 cases of sepsis occur annually. This rate is expected to climb, with an additional 1 million cases per year expected by 2020. These infection-induced inflammatory syndromes ultimately lead to organ dysfunction, and a significantly high mortality rate. Recently, advances in knowledge of sepsis syndrome have led to progress in identifying potential treatment options beyond our current standards of care. Many health care facilities have implemented protocols to guide clinicians to use such standards: early goal-directed therapy and activated protein C therapy in qualifying patients. Nonetheless, debate continues to confuse identification of patient populations in whom corticosteroid therapy should be recommended. While the data describing studies of novel treatment approaches has been controversial in some cases, there have been promising results observed in others. Here we review several treatments that have recently gained attention in the medical literature: HMG-CoA reductase inhibitors (statins), selenium therapy, immunoglobulin therapy, and several agents currently in preclinical study.

Key Words: sepsis • septic shock • intensive care unit • alternative treatments • critical care

This version was published on October 1, 2008

Journal of Pharmacy Practice, Vol. 21, No. 5, 371-379 (2008)
DOI: 10.1177/0897190008318233


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?